Search

A quality of life tool developed by disability researcher Jenny Downs is helping to reveal the difference specific interventions can make to the lives of children and families living with disability.

Video technology is helping researchers learn more about the earliest features of autism, and in turn is helping families gain access to better interventions.

Ask our experts a question about the COVID-19 pandemic.
Research
VaccinationVaccination is the injection of an inactivated bacteria or virus into the body. This simulated infection allows an individual's immune system to develop an adaptive immunity for protection against that type of illness. When a sufficiently large percentage of a population has been vaccinated, this results in herd immunity.
Research
MeningitisMeningitis is when the membranes that surround the brain and spinal cord (meninges) become infected by the bacteria Neisseria meningitidis.
Research
Tourette SyndromeOccurring in 1% of school-aged children, Tourette syndrome is a neurodevelopmental disorder characterised by uncontrollable movements and vocalisations known as tics.
Research
Long-Term Outcome of Young Infants With Suspected Neuroblastoma following Observation as Primary Therapy: A Report From the Children's Oncology GroupSeveral studies have established that patients with localized perinatal neuroblastoma can be safely observed; however, long-term outcomes have not been previously reported. We evaluated long-term outcomes of infants with suspected perinatal neuroblastoma enrolled on the Children's Oncology Group ANBL00P2, which included an expectant observation approach.
Research
TANGO2 binds crystallin alpha B and its loss causes desminopathyMutations in the TANGO2 gene cause an autosomal recessive disorder characterised by developmental delay, stress-induced episodic rhabdomyolysis, and cardiac arrhythmias along with severe metabolic crises. Although TANGO2 mutations result in a well characterised disease pathology, the function of TANGO2 is still unknown.
Research
Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPEThe pivotal phase 3 EPITOPE trial, a 12-month, double-blind, placebo-controlled study of epicutaneous immunotherapy with the VIASKIN patch containing 250 μg of peanut protein (VP250), previously reported significant treatment response versus placebo in peanut-allergic toddlers aged 1 through 3 years.
Research
Diaphragm Function in Very Preterm Infants at 36 Weeks' Postmenstrual AgeUnderstand how bronchopulmonary dysplasia (BPD) and antenatal and postnatal factors influence diaphragmatic functional effectiveness in very preterm infants.